Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells
View through CrossRef
Abstract
Purpose
This study aims to investigate the effect of Niraparib in combination with an Anti-GD2 Antibody on osteosarcoma cells.
Methods
Scratch test was utilized to assess cell migration capacity, while the Transwell experiment was utilized to evaluate cell invasion potential. Cell proliferation was measured using the CCK8 experiment. The affinity between the anti-GD2 antibody and its antigen was determined via ELISA. Tumor growth was evaluated through animal experiments. Western blotting, QRT-PCR, and histological analysis were conducted to examine the expression of relevant proteins and mRNAs.
Results
MG63 cell line was used for an example. The scratch test showed that the migration rate of osteosarcoma cells in Niraparib + Anti-GD2 group was 1.07 ± 0.04 after 48 h, and 0.34 ± 0.04 in the Control group. Transwell experiment showed that the invasion ability of osteosarcoma cells in Niraparib + Anti-GD2 group was 21.0 ± 1.5, and that in Control group was 87.7 ± 2.9. CCK8 experiment showed that the absorbance value of Niraparib + Anti-GD2 group was 0.16 ± 0.10 on day 5, and that of the Control group was 0.76 ± 0.09. Western blotting showed that the expression levels of BALP and CICP in Niraparib + Anti-GD2 group were 0.751 ± 0.135 and 1.086 ± 0.115, respectively, and those in Control group were 1.025 ± 0.143 and 1.216 ± 0.168, respectively. QRT-PCR results showed that the absorbance values of Niraparib + Anti-GD2 group were 0.173 ± 0.065 and 0.170 ± 0.078 on day 14. The results of animal experiments showed that on day 5, the tumor volume of the Control group was 2433 ± 391, and that of the Niraparib + Anti-GD2 group was 1137 ± 148. Histological analysis showed that the mean density values of Niraparib + Anti-GD2 group were 0.19 ± 0.08 and 0.22 ± 0.07, and those of Control group were 0.26 ± 0.09 and 0.29 ± 0.10.
Conclusion
The combination of Niraparib and Anti-GD2 antibody significantly inhibits Osteosarcoma cells.
Springer Science and Business Media LLC
Title: Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells
Description:
Abstract
Purpose
This study aims to investigate the effect of Niraparib in combination with an Anti-GD2 Antibody on osteosarcoma cells.
Methods
Scratch test was utilized to assess cell migration capacity, while the Transwell experiment was utilized to evaluate cell invasion potential.
Cell proliferation was measured using the CCK8 experiment.
The affinity between the anti-GD2 antibody and its antigen was determined via ELISA.
Tumor growth was evaluated through animal experiments.
Western blotting, QRT-PCR, and histological analysis were conducted to examine the expression of relevant proteins and mRNAs.
Results
MG63 cell line was used for an example.
The scratch test showed that the migration rate of osteosarcoma cells in Niraparib + Anti-GD2 group was 1.
07 ± 0.
04 after 48 h, and 0.
34 ± 0.
04 in the Control group.
Transwell experiment showed that the invasion ability of osteosarcoma cells in Niraparib + Anti-GD2 group was 21.
0 ± 1.
5, and that in Control group was 87.
7 ± 2.
9.
CCK8 experiment showed that the absorbance value of Niraparib + Anti-GD2 group was 0.
16 ± 0.
10 on day 5, and that of the Control group was 0.
76 ± 0.
09.
Western blotting showed that the expression levels of BALP and CICP in Niraparib + Anti-GD2 group were 0.
751 ± 0.
135 and 1.
086 ± 0.
115, respectively, and those in Control group were 1.
025 ± 0.
143 and 1.
216 ± 0.
168, respectively.
QRT-PCR results showed that the absorbance values of Niraparib + Anti-GD2 group were 0.
173 ± 0.
065 and 0.
170 ± 0.
078 on day 14.
The results of animal experiments showed that on day 5, the tumor volume of the Control group was 2433 ± 391, and that of the Niraparib + Anti-GD2 group was 1137 ± 148.
Histological analysis showed that the mean density values of Niraparib + Anti-GD2 group were 0.
19 ± 0.
08 and 0.
22 ± 0.
07, and those of Control group were 0.
26 ± 0.
09 and 0.
29 ± 0.
10.
Conclusion
The combination of Niraparib and Anti-GD2 antibody significantly inhibits Osteosarcoma cells.
Related Results
Combined Use of Niraparib Enhanced the Inhibitory Effect of Anti-GD2 Antibody on Osteosarcoma Cells
Combined Use of Niraparib Enhanced the Inhibitory Effect of Anti-GD2 Antibody on Osteosarcoma Cells
Abstract
Purpose
To study the inhibitory effect of Niraparib in combination with Anti-GD2 Antibody on Osteosarcoma.
Methods
The migration ability of OS cells was detected...
Abstract 1528: GD2+ breast cancer stem cell growth is dependent on NFκB signaling and suppressed by the IKK inhibitor BMS345541 in vitro and in vivo
Abstract 1528: GD2+ breast cancer stem cell growth is dependent on NFκB signaling and suppressed by the IKK inhibitor BMS345541 in vitro and in vivo
Abstract
Recurrence of breast cancer after treatment could be caused by breast cancer stem-like cells (BCSCs) or breast cancer-initiating cells. Therefore, targeting...
Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition
Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition
Background/Objectives: High-risk neuroblastoma patients are treated with approved anti-ganglioside GD2 antibodies of moderate (dinutuximab beta; DB) and higher binding affinity (na...
Abstract 1261: Targeting IL-11Rα inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model
Abstract 1261: Targeting IL-11Rα inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model
Abstract
Osteosarcoma is the most common primary tumor of bones. In the past three decades treatment paradigms and survival rates have not improved. While osteosarco...
Abstract A18: Comprehensive identification of bone cancer driver genes by using Li-Fraumeni syndrome iPSCs
Abstract A18: Comprehensive identification of bone cancer driver genes by using Li-Fraumeni syndrome iPSCs
Abstract
Osteosarcoma, the primary malignant tumor of bone, is the most frequent primary non-hematologic malignancy in children and adolescents. Despite the advances...
Abstract B017: Precision Nanotherapy for the Treatment of Progressive Neuroblastoma
Abstract B017: Precision Nanotherapy for the Treatment of Progressive Neuroblastoma
Abstract
Deadly progressive neuroblastoma (pNB) that defy current clinical therapy is a devastating pediatric malignancy with f...
T Cell Modulation Combined with Intratumoral CpG Cures Lymphoma without the Need for Chemotherapy.
T Cell Modulation Combined with Intratumoral CpG Cures Lymphoma without the Need for Chemotherapy.
Abstract
Introduction: We have previously shown that intratumoral injection of CpG oligodeoxynucleotide plus systemic chemotherapy can induce T cell immunity against...
Abstract 1637: GPX4-mediated Pathway Regulates Iron Efflux to Prevent Ferroptotic Cell Death and Promote Immunosuppressive Signals in Osteosarcoma Cells
Abstract 1637: GPX4-mediated Pathway Regulates Iron Efflux to Prevent Ferroptotic Cell Death and Promote Immunosuppressive Signals in Osteosarcoma Cells
Abstract
Osteosarcoma is a malignant bone sarcoma prevalent in children, adolescents, and young adults, with limited treatment options. Targeting ferroptosis, an iro...